Industry veterans join executive team as VP,
Market Access and VP, Employer Markets
Shaun M. O'Neil
promoted to Lucid's President and COO
NEW
YORK, Nov. 16, 2023 /PRNewswire/
-- Lucid Diagnostics Inc. (Nasdaq:
LUCD) ("Lucid" or the "Company") a commercial-stage,
cancer prevention medical diagnostics company, and majority-owned
subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ( "PAVmed"),
announced that the Company has strengthened and expanded its
executive team with two industry veterans to support its critical
market access and direct contracting efforts. Natalie S. Carfora joins Lucid as Vice
President, Market Access, and James M.
Fricchione as Vice President, Employer Markets. In
conjunction with this expansion, Shaun M.
O'Neil will now serve as Lucid's President and Chief
Operating Officer.
"We are intensely focused on driving EsoGuard® payor
coverage and securing direct contracts with employers and other
self-insured entities—initiatives which are critical to Lucid's
success in translating test volume growth into revenue and revenue
growth," said Lishan Aklog, M.D.,
Lucid's Chairman and Chief Executive Officer. "To that end, I am
excited to welcome Natalie Carfora
and Jim Fricchione, two seasoned
industry veterans with extensive market access and direct
contracting experience, to the Lucid team. I am also grateful that
Shaun O'Neil has agreed to expand
his responsibilities and serve as Lucid's President, with a strong
focus on ensuring that these market access and direct contracting
efforts are tightly coordinated with our successful commercial,
clinical research, and laboratory operations."
Natalie Carfora brings over a
decade of experience and expertise in market access and sales in
the medical diagnostics industry, including successfully engaging
with commercial and governmental payors on coverage policy. She
most recently served as Head of Market Access of an innovative
molecular diagnostic company focused on commercializing a
blood-based test for pancreatic cancer. She previously held market
access and commercial roles at Myriad Genetics and Eli Lilly .
In these roles, Ms. Carfora successfully led and supported a
variety of market access initiatives, including collaborating with
clinical research teams on study design, driving pilot programs
with payors and self-funded clients, as well as utilizing clinical
utility studies to inform broader coverage policies.
Jim Fricchione brings over two
decades of successful national health benefits experience, leading
sales and service teams in markets across the country, including
health and wellness benefits for employer groups. He most recently
served as Senior Vice President, Sales & Account Management, at
Cobalt Benefit Group, a large Blue Cross-owned Third-Party
Administrator (TPA). Mr. Fricchione brings a strong network of
relationships in the benefits management ecosystem, including
brokers, TPAs, self-funded employers, and Administrative Services
Only organizations (ASOs).
Shaun O'Neil is an industry
veteran with over two decades of experience in the medical
technology sector and serves as PAVmed's Executive Vice President
and Chief Operating Officer. Mr. O'Neil has concurrently served in
leadership roles at Lucid since its inception, first as Vice
President and Chief Commercial Officer and then as Executive Vice
President and Chief Operating Officer since April 2022. He has played a primary role in
designing and building Lucid's commercial, market access, and
revenue cycle management infrastructure; executing its commercial
strategy, including the launch of Lucid Test Centers and #CYFT
Testing Events; and overseeing the launch of its commercial
laboratory, LucidDx Labs. Prior to PAVmed and Lucid, Mr. O'Neil
served in various sales and marketing leadership positions with
AngioDynamics.
About Lucid Diagnostics
Lucid Diagnostics Inc. is a
commercial-stage, cancer prevention medical diagnostics company,
and subsidiary of PAVmed Inc. Lucid is focused on the millions of
patients with gastroesophageal reflux disease (GERD), also known as
chronic heartburn, who are at risk of developing esophageal
precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test,
performed on samples collected in a brief, noninvasive office
procedure with its EsoCheck® Esophageal Cell Collection Device -
the first and only commercially available tools designed with the
goal of preventing esophageal cancer and cancer deaths through
widespread, early detection of esophageal precancer in at-risk
patients.
For more information, please visit luciddx.com and for
more information about its parent company PAVmed, please
visit pavmed.com.
Forward-Looking Statements
This press release includes
forward-looking statements that involve risk and uncertainties.
Forward-looking statements are any statements that are not
historical facts. Such forward-looking statements, which are based
upon the current beliefs and expectations of Lucid Diagnostics'
management, are subject to risks and uncertainties, which could
cause actual results to differ from the forward-looking statements.
Risks and uncertainties that may cause such differences include,
among other things, volatility in the price of Lucid Diagnostics'
common stock; general economic and market conditions; the
uncertainties inherent in research and development, including the
cost and time required to advance Lucid Diagnostics' products to
regulatory submission; whether regulatory authorities will be
satisfied with the design of and results from Lucid Diagnostics'
clinical and preclinical studies; whether and when Lucid
Diagnostics' products are cleared by regulatory authorities; market
acceptance of Lucid Diagnostics' products once cleared and
commercialized; Lucid Diagnostics' ability to raise additional
funding as needed; and other competitive developments. In addition,
Lucid Diagnostics continues to monitor the COVID-19 pandemic and
the pandemic's impact on Lucid Diagnostics' businesses. These
factors are difficult or impossible to predict accurately and many
of them are beyond Lucid Diagnostics' control. In addition, new
risks and uncertainties may arise from time to time and are
difficult to predict. For a further list and description of these
and other important risks and uncertainties that may affect Lucid
Diagnostics' future operations, see Part I, Item 1A, "Risk
Factors," in Lucid Diagnostics' most recent Annual Report on Form
10-K filed with the Securities and Exchange Commission, as the same
may be updated in Part II, Item 1A, "Risk Factors" in any Quarterly
Report on Form 10-Q filed by Lucid Diagnostics after its most
recent Annual Report. Lucid Diagnostics disclaims any intention or
obligation to publicly update or revise any forward-looking
statement to reflect any change in its expectations or in events,
conditions, or circumstances on which those expectations may be
based, or that may affect the likelihood that actual results will
differ from those contained in the forward-looking statements.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-strengthens-and-expands-market-access-and-direct-contracting-efforts-301990790.html
SOURCE Lucid Diagnostics